Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v. - Matuskova H; Marasek P; Mazhara V; Simonova E; Kosinova L; Danek P; Danova K; Sajnerova K; Malatova I; Hrabankova K; Greco D; Martinec O; et al. (Journal for immunotherapy of cancer, 2025)